Specifically, BrCa patients bearing HSPB2-positive tumors had a significantly shorter OS time interval than those with lower HSPB2 mRNA levels (HR = 2.45, 95% CI = 1.23–4.96, p = 0.011). The gene discussed is HSPB2; the disease is invasive breast carcinoma.